Company profile
Shanghai Cell Therapy Group Co., Ltd.
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CD19, CD22, and BCMA (tri-antigen) | Systemic Lupus Erythematosus | |
| Phase 1 | CD19, CD20, and BCMA (tri-target)Cell therapy | Multiple Myeloma |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.